ZymoGenetics, Inc. (NASDAQ: ZGEN) 9% LOWER; today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM Thrombin, topical (Recombinant).
Effective January 1, 2010, ZymoGenetics regains full promotion rights in the United States and all ex-U.S. rights except in Canada, where Bayer will market and sell the product. Click here to see the full report.
Clarient, Inc. (NASDAQ: CLRT) 8% HIGHER; today announced that it...
Post new comment